Introduction
A new family of structurally related, growth regulatory proteins has been recently identi®ed on the basis of their expression patterns and functional activities. These secreted, cysteine-rich proteins have been named members of the`CCN family' (for Cyr61/Cef10, CTGF/Fisp12, and Nov; Bork, 1993) and include at least three distinct members: cyr61/cef10 (Simmons et al., 1989; O'Brien et al., 1990) , CTGF/®sp12 (Bradham et al., 1991; Ryseck et al., 1991) and nov Joliot et al., 1992) . Members of this protein family share a high level of sequence homology, including complete conservation of 38 cysteine residues in their secreted portion. Speci®c, though diverse, growth-regulatory activities have been detected for members of the CCN family, supporting the notion that these proteins may play interesting and important roles in growth control.
Both cyr61 (O'Brien et al., 1990; Nathans, 1985, 1987) and ®sp12 (Ryseck et al., 1991) were identi®ed as immediate-early genes, whose transcription is rapidly induced by serum growth factors without requiring de novo protein synthesis (Williams et al., 1992; Herschmann, 1991; Lau and Nathans, 1991) . cef10, the chicken ortholog of cyr61, was also cloned as a growth factor-and v-src-inducible immediate-early gene (Simmons et al., 1989) . ®sp12 was later found to be the mouse homolog of the human connective tissue growth factor (CTGF; Bradham et al., 1991) , which was identi®ed by virtue of its mitogenic activity in human umbilical vein endothelial cells (HUVECs; Bradham et al., 1991) . CTGF is also mitogenic for ®broblasts in culture and is expressed in dermal ®broblasts during wound healing (Igarashi et al., 1993; Frazier et al., 1996) . nov was ®rst identi®ed in chicken as an aberrantly expressed gene in retrovirus-induced avian nephroblastomas (Joliot et al., 1992) . An N-terminal deletion of Nov is able to transform chicken embryo ®broblasts (Joliot et al., 1992) , and the human ortholog novH was found to be associated with various human tumors such as Wilm's tumor (Martinerie et al., 1994) . Thus, members of the CCN family include several proteins encoded by growth factor-inducible immediate-early genes, a connective tissue growth factor, and a protein with oncogenic potential.
Like other immediate-early genes, cyr61 is not expressed in quiescent cells but is rapidly induced upon stimulation by serum, platelet-derived growth factor (PDGF), basic ®broblast growth factor (bFGF; Nathans, 1985, 1987; O'Brien et al., 1990) , transforming growth factor-b (Brunner et al., 1991) , or the tumor promoter TPA (12-O-tetradecanolyl-phorbol-13-acetate) in tissue culture and in regenerating liver in rodents (Nathans et al., 1988) . cyr61 encodes a 40 kDa secreted, heparin-binding protein which associates with the extracellular matrix (ECM) and cell surface (Yang and Lau, 1991) . Cell surface-associated Cyr61 is rapidly internalized and degraded via a lysosomal pathway, suggesting interaction with a speci®c cell surface receptor (Kireeva et al., 1997) .
Puri®ed recombinant murine Cyr61 mediates cell adhesion for ®broblasts, endothelial cells, and epithelial cells (Kireeva et al., 1996 (Kireeva et al., , 1997 . Cyr61 also induces chemotaxis in ®broblasts (Kireeva et al., 1996) , and enhances growth factor-stimulated DNA synthesis in both ®broblasts and endothelial cells (Kireeva et al., 1996 (Kireeva et al., , 1997 . These activites suggest that Cyr61 may act as a mediator of growth factors that stimulate its synthesis, thereby modulating cellular processes that involve cell adhesion, migration, and proliferation. In vivo, cyr61 is expressed during embryonic development in a temporally regulated and tissue-speci®c manner (O'Brien and Lau, 1992) . In particular, its expression correlates with dierentiation of mesenchymal cells into chondrocytes, suggesting a possible role of cyr61 in chondrocyte dierentiation (O'Brien and Lau, 1992).
Indeed, the mouse Cyr61 protein has been recently shown to promote chondrogenic dierentiation in mouse limb bud mesenchymal cells in the micromass culture system (Wong et al., 1998) .
Here we report the cloning of the human CYR61 cDNA, tissue-speci®c expression of hCYR61 mRNA in adult human tissues and puri®cation of recombinant human CYR61 (hCYR61) protein in biologically active form. Puri®ed recombinant hCYR61 protein enhances bFGF-induced DNA synthesis in HUVECs. Furthermore, we have elucidated the mechanism of action of hCYR61 in this process: hCYR61 displaces bFGF from the ECM, thus increasing the eective concentration of bFGF. The possible implications of these ®ndings are discussed.
Results
Cloning and expression of the hCYR61 cDNA Analysis of cyr61 expression during mouse embryonic development revealed a high level of expression in the placenta (O'Brien and Lau, 1992) , making it logical to isolate the hCYR61 cDNA from a human placental library. As a probe we used a human-sequence-speci®c cDNA fragment, which was generated by PCR of cDNAs reverse transcribed from total RNA isolated from logarithmically growing WI-38 human ®broblasts. For the PCR reaction, degenerate primers derived from sequences corresponding to the most conserved regions of known members of the cyr61 family were used (O'Brien and Lau, 1992) . From a total of 5610 5 clones of the human placental l cDNA library screened, 10 3 (0.2%) hybridized to the cyr61 probe. Five of the positive clones were plaque-puri®ed and the one containing the longest insert (1935 nt) was chosen for further analysis and sequence determination. The human CYR61 cDNA sequence so determined (GenBank accession number AF003594) is identical to that reported recently (Jay et al., 1997) and displays 85% overall homology with the mouse cyr61 cDNA sequence, with 87% sequence identity in the coding region and 67% sequence identity in the 5'-untranslated region. Surprisingly, the 3'-untranslated region is more conserved than the coding region with 91% sequence identity; this might re¯ect its role in the regulation of mRNA turnover (Shaw and Kamen, 1986) . The deduced hCYR61 protein is 381 amino acids long including the N-terminal secretory signal, shares all 38 cysteine residues shared among all members of this protein family, and contains 91% sequence identity with its mouse homolog (O'Brien and Lau, 1992) .
Consistent with its expression pattern in mouse ®broblasts (O'Brien et al., 1990) , hCYR61 mRNA was not detected in quiescent human skin ®broblasts, but was abundant in logarithmically growing and serumstimulated cells (Figure 1a ). hCYR61 mRNA was superinduced when human skin ®broblasts were stimulated by serum in the presence of cycloheximmide (Figure 1a ), con®rming that hCYR61 is an immediate-early gene in human ®broblasts. To investigate the tissue-speci®c expression, we analysed poly(A) + RNA from various human tissues and compared the expression pattern of hCYR61 to those of CTGF, and NovH (Figure 1b) . hCYR61 mRNA was present at relatively high levels in the human heart, lung, skeletal muscle and placenta, and was present at a moderate level in the pancreas and low to undetectable levels in the brain, kidney and liver. These results are consistent with cyr61 expression in the mouse (O'Brien and Lau, 1992; O'Brien et al., 1990) . The expression pattern of CTGF was similar to that of hCYR61, except that CTGF mRNA level was high in the kidney where hCYR61 mRNA was undetectable. In contrast, the expression pattern of novH was substantially dierent, with signi®cant expression in the heart, brain, and pancreas, and relatively low levels of expression in other tissues examined (Figure 1b) .
Puri®cation of hCYR61 protein
We used the baculovirus expression system as a means of producing recombinant hCYR61 protein, which is secreted into and can be isolated from conditioned media of Sf9 insect cells programmed for its synthesis. (Bradham et al., 1991) , novH (Martinerie et al., 1994) , or b-actin. Tissues used as a source of mRNA are as indicated. Molecular sizes of RNAs (kb) are indicated at right Recombinant hCYR61 was puri®ed from the culture medium as described in Materials and methods, and the protein preparations were analysed by SDS ± PAGE and Western blot analysis ( Figure 2 ). Typically, 1 mg of CYR61 protein of greater than 90% purity can be isolated from 500 ml of conditioned medium.
hCYR61 augments bFGF-induced DNA synthesis in HUVECs
The growth of HUVECs is absolutely dependent upon the presence of FGF, which cannot be substituted by the presence of fetal bovine serum (Gar®nkel et al., 1996) . While the murine mCyr61 has no detectable mitogenic activity by itself, it enhances bFGF-induced DNA synthesis in both HUVECs and ®broblasts (Kireeva et al., 1996 (Kireeva et al., , 1997 . Likewise, we found that the recombinant hCYR61 protein alone did not stimulate [ 3 H]thymidine incorporation in HUVECs, but was able to enhance bFGF-induced DNA synthesis in a manner similar to that of the mouse homolog ( Figure 3 ). This eect is inhibitable by neutralizing anti-Cyr61 antibody but not by preimmune serum or unrelated antibodies (Kireeva et al., 1996 (Kireeva et al., , 1997 and can be attributable to hCYR61 ( Figure  3 ).
While these experiments were carried out in F12 medium, we observed that the bFGF-and hCYR61-dependencies of DNA synthesis of HUVECs in Endothelial Serum-Free Medium (Endo-SFM) were somewhat dierent. In F12 medium, hCYR61 enhanced bFGF-induced DNA synthesis 2 ± 3-fold, even when bFGF was present at relatively high concentrations (10 ng/ml; Figure 3 ) (Kireeva et al., 1997) . Thus, Cyr61 increases the maximal amount of [ 3 H]thymidine incorporated at various bFGF concentrations, rather than reduces the optimal concentration of bFGF (data not shown). When cultured in Endo-SFM, a doseresponse determination showed that maximal [ 3 H]thymidine incorporation was reached at less than 5 ng/ml of bFGF in Endo-SFM ( Figure 4a ). Under these conditions, hCYR61 enhanced the DNA synthesis-stimulation eect of suboptimal doses of bFGF but did not aect the maximal level of DNA synthesis at high bFGF concentrations ( Figure 4b ). The dierence between F12 medium and Endo-SFM is that Endo-SFM is optimized for HUVECs growth under serum-free conditions; the only additional component needed to support HUVECs growth in Endo-SFM is bFGF. F12 medium must be supplemented with 10% FBS and ECGS (endothelial cell growth supplement, or brain extract, which provides bFGF) in order to support HUVECs growth. To understand the nature of hCYR61-enhanced DNA synthesis better, we have employed Endo-SFM under serum-free conditions to monitor DNA synthesis in HUVECs.
hCYR61 increases the eective concentration of bFGF
The cooperative eects of hCYR61 and bFGF to stimulate DNA synthesis may be explained by at least two distinct, though not mutually exclusive, plausible mechanisms. The ®rst hypothesis postulates interaction between hCYR61 and its speci®c cell-surface receptor; signaling resulting from this interaction may converge with signals induced by bFGF, leading to enhanced DNA synthesis. Alternatively, hCYR61 may increase thymidine uptake through interactions with the cell surface, thereby changing the cellular precursor pool for DNA synthesis. This scenario predicts that neutralizing anti-Cyr61 antibodies added simultaneously with or prior to the addition of hCYR61 to target cells will block hCYR61 binding with the receptor, thus inhibiting hCYR61 action as a consequence.
Another hypothesis is based on the fact that bFGF and hCYR61 are both heparin-binding proteins that associate with the ECM, most likely through binding to heparan sulfate proteoglycans (HSPGs). It can be envisaged that hCYR61 may displace bFGF from its binding sites in the ECM, thus increasing the bioavailability or eective concentration of bFGF, resulting in enhanced mitogenic response. This scenario predicts that neutralizing anti-Cyr61 antibodies act by preventing hCYR61 interaction with the ECM, thus interfering with hCYR61 competition with (or displacement of) bFGF binding to the ECM. If this were true, neutralizing antibodies can exert their eect only if added to hCYR61 prior to an opportunity for hCYR61 to interfere with the interaction between bFGF and the ECM (as opposed to target cells). These two scenarios are not mutually exclusive and may operate independently or simultaneously under different conditions.
To assess the validity of these two possibilities, HUVECs were grown in Endo-SFM for the following experiment ( Figure 5 ). To a control set of HUVECs cells were added Endo-SFM containing dierent combinations of bFGF, hCYR61 and neutralizing anti-Cyr61 antibodies. For the experimental samples, a set of the cell-free plates coated with the ECM were prepared from con¯uent HUVEC cultures. To accomplish this, HUVECs were grown to con¯uence, lysed with Triton X-100 and ammonium hydroxide, and washed extensively to remove cell debris. The cell-free ECM-coated plates were then used to prepare two types of conditioned media. One set of plates were treated with medium containing bFGF, hCYR61, and anti-Cyr61 antibodies. In this situation the antibodies can react with hCYR61 in the presence of the ECM. Another set of plates were treated with bFGF and Cyr61, but not anti-Cyr61 antibodies. Both sets of conditioned media were then added to naive dishes of HUVECs. Anti-Cyr61 antibodies were added to the medium conditioned in the absence of antibodies just prior to the addition to target cells. Thus, the two sets of experimental plates contained the same additives, but the order of addition was dierent.
Results of this experiment are shown in Figure 6 . While hCYR61 by itself did not induce DNA synthesis, it was able to enhance the mitogenic eect of bFGF (Figure 6a ). Neutralizing anti-Cyr61 antibodies inhibited the eect of hCYR61 if added simultaneously with bFGF and hCYR61 directly to the cells (Figure 6a and neutralizing anti-Cyr61 antibody were added directly to quiescent HUVECs. In experimental samples (right), media containing the above additives were preincubated with dishes containing cell-free ECM prior to addition to HUVECs. Neutralizing anti-Cyr61 antibody was added either prior to (2) or after (1) preincubation with the ECM. Results of the experiment are shown in Figure 6 prior to incubation of the medium with the ECM (Figure 6b ). When anti-Cyr61 antibodies were added to the medium preincubated with the ECM, they did not inhibit the cooperative eect of hCYR61 and bFGF in the stimulation of DNA synthesis in HUVECs ( Figure  6b ). These results indicate that the enhancement eect of hCYR61 on bFGF-induced DNA synthesis under these conditions is mediated through hCYR61-matrix interactions. We interpret these results to suggest that hCYR61 augments bFGF-induced DNA synthesis by displacing bFGF from the ECM, thus increasing the eective concentration of bFGF available to the cells.
hCYR61 can displace bFGF from the ECM
To address directly the question of whether hCYR61 is capable of displacing bFGF from the ECM, we measured the release of iodinated bFGF from the ECM in the presence or absence of hCYR61 ( Figure  7 ). hCYR61 was able to displace bFGF from the ECM of HUVECs in a time-dependent manner. Up to 8 ± 10% of ECM-bound bFGF can be displaced by hCYR61; a comparable percentage of bFGF can also be released by thrombin (Benezra et al., 1993) , a serum protease shown to activate bFGF by releasing it from ECM storage. Taken together, these data are consistent with the interpretation that hCYR61 augments bFGFinduced DNA synthesis in HUVECs through the displacement of bFGF from the ECM to increase its eective concentration.
Discussion
CYR61 is a member of a family of structurally conserved proteins that includes the connective tissue growth factor and the proto-oncoprotein Nov (Joliot et al., 1992; Bradham et al., 1991) . CYR61 is encoded by an immediate-early gene and is synthesized upon stimulation by serum growth factors, including bFGF (Lau and Nathans, 1987; O'Brien et al., 1990) . The functions of CYR61, and perhaps those of members of the protein family, may act to help mediate the cellular responses of the growth factors that induce CYR61 synthesis. Consistent with this hypothesis, our laboratory has detected several activities of CYR61: it promotes cell adhesion, stimulates chemotaxis, and augments growth factor-induced DNA synthesis (Kireeva et al., 1996 (Kireeva et al., , 1997 . In this communication we report the cloning of the human CYR61 cDNA, expression and puri®cation of the hCYR61 protein, and we show that hCYR61 enhances bFGF-induced DNA synthesis in HUVECs. Furthermore, we show that hCYR61 acts by displacement of bFGF from its binding sites in the ECM of HUVECs, thus increasing the eective concentration of bFGF (Figures 6 and 7) . Although this mechanism of action does not exclude the possibility that hCYR61 may bind to a speci®c cell-surface receptor to induce mitogenic signaling, it may suggest a dierent outcome from the latter. By increasing the eective concentration of bFGF, cellular responses to the full range of bFGF activities may be increased, not only DNA synthesis. If hCYR61 acts exclusively through interaction with its own distinct receptor, then the signaling consequences may be dierent from those of bFGF. In addition, this displacement mechanism may be particularly important when the bFGF concentration is limiting (Figure 4) . Thus, a scenario may be envisaged where bFGF stimulation of cells may lead to the synthesis of hCYR61, which, in turn, displaces residual FGF from the ECM for further stimulation of the cells.
Since many extracellular proteins can bind heparin in vitro, it might be argued that the ability to displace bFGF is a non-speci®c activity of heparin-binding proteins. Two sets of observations indicate that this is not the case. First, in one study three major plasma heparin-binding proteins were tested for their ability to compete with FGF for HSPGs on the cell surface and the ECM (Brown and Parish, 1994) . Platelet factor 4 (PF4) was able to compete with iodinated bFGF for binding to the ECM, histidine-rich glycoprotein (HRG) was able to both prevent bFGF from binding to the ECM and to displace it, whereas antithrombin III (ATIII) had no eect. Second, the heparin-binding proteins thrombospondin, vitronectin and b-thromboglobulin do not modulate bFGF-induced DNA synthesis whereas PF4 and HRG do (Kireeva et al., 1997; Brown and Parish, 1994; Watson et al., 1994) , correlating with their abilities to displace bFGF. These proteins (PF4 and HRG) were active in the same concentration range (75 ± 125 nM) as that of hCYR61 (75 nM) observed to displace bFGF. It is likely that dierent heparin-binding proteins may interact with various saccharide sequences on the heparan-sulfate chains of HSPGs with distinct anities, thus accounting for the dierential abilities to displace each other from the ECM.
The presence of heparin-binding proteins may either stimulate or inhibit the action of bFGF (Watson et al., 1994) . Both PF4 and HRG have been observed to inhibit rather than stimulate bFGF-induced mitogenesis in NIH3T3 cells in a heparin-dependent manner (Brown and Parish, 1994; Watson et al., 1994) . It was proposed that both proteins can act as either positive or negative regulators of FGF action: they can act positively by displacing FGF from the ECM and basement membrane and making more FGF available to responsive cells, and negatively by masking HSPGs on responsive cells and preventing FGF receptor activation (Brown and Parish, 1994) . Thus, the stimulatory or inhibitory eect of these proteins on FGF-induced mitogenesis may be determined by the ratio of HSPG in the ECM and the cell surface.
hCYR61 is capable of augmenting growth factorinduced DNA synthesis in both ®broblasts and HUVECs (Kireeva et al., 1996 (Kireeva et al., , 1997 , and over a wide concentration range of bFGF, depending on the culture conditions. Under serum-free conditions in Endo-SFM, hCYR61 enhances DNA synthesis when bFGF concentration is limiting (Figure 4 ). In the serum-containing medium F12, hCYR61 enhances DNA synthesis even at high concentrations of bFGF (Kireeva et al., 1996 (Kireeva et al., , 1997 , suggesting a mechanism of action that is distinct from growth factor displacement. How these culture models re¯ect in vivo situation is not clear at present. The interplay between bFGF, hCYR61, and available matrix proteins that can modulate their function is likely to be complex and may be speci®c to various organ systems at distinct times of development. However, it is plausible to speculate that the cooperation of FGF and CYR61 in stimulating mitogenesis is perhaps most relevant when growth factor concentration is limiting. Such circumstances may arise during the process of wound healing and in speci®c stages in development. Both CYR61 and the structurally related CTGF are induced in dermal ®broblasts during wound healing (Igarashi et al., 1993; Latinkic, 1994) . Since both CYR61 and CTGF are chemotactic for ®broblasts, and CTGF is mitogenic (Bradham et al., 1991) whereas CYR61 enhances bFGF-induced DNA synthesis (Figure 3) , these protein may function to enhance both migration and proliferation of dermal ®broblasts for wound repair.
CYR61 may also cooperate with FGF during embryogenesis with respect to its activity in enhancing DNA synthesis and other bFGF associated activities. During mouse embryogenesis, expression of cyr61 mRNA and localization of the Cyr61 protein correlate with developing cardiovascular system (Latinkic, 1994; O'Brien and Lau, 1992) . The eects of Cyr61 on the adhesion and proliferation of endothelial cells are consistent with its potential role in the development of the cardiovascular system. Another prominent site of cyr61 expression is in mesenchymal cells differentiating into cartilaginous skeleton (O'Brien and Lau, 1992) . We have shown that Cyr61 can directly promote the chondrogenic dierentiation of mouse limb mesenchymal cells in micromass cultures (Wong et al., 1998) . Given the role of FGF signaling mechanism in development of the embryonic skeleton (Niu et al., 1997; Muenke and Schell, 1995; Ishigaki et al., 1997; Deng et al., 1997) , it remains possible that CYR61 may interact and cooperate with FGF function in this organ system.
Our ®ndings suggest the possibility that hCYR61 may be able to release other ECM-associated growth factors or signaling molecules through displacement mechanism. In addition, other members of the hCYR61 protein family, such as CTGF and Nov, may also be capable of a similar activity. These possibilities can be addressed in future investigations.
Materials and methods

Cell culture
Early passage HUVECs (ATCC CRL 1730) were maintained in F12 medium supplemented with 10% FBS CYR61 displaces bFGF from the ECM to enhance DNA synthesis TV Kolesnikova and LF Lau (Intergene), 100 mg/ml heparin (Gibco BRL) and 30 mg/ml endothelial cell growth supplement (Collaborative Biomedical Products). Endo-SFM (Gibco BRL) was used where indicated. Human skin ®broblasts (HSF; ATCC) and W138 ®broblasts (ATCCCCL-75) were grown in DMEM supplemented with 10% FBS. NIH3T3 ®broblasts were grown in DMEM supplemented with 10% calf serum. Quiescent HSFs were prepared by growth to con¯uence in DMEM supplemented with 10% FBS, followed by exposure to DMEM containing 0.1% FBS for 2 days. Serum stimulation was carried out by exposure to DMEM plus 20% FBS for 1 h. Where indicated, quiescent cells were treated with cycloheximide (10 mg/ml) added together with serum for 3 h.
Cloning of human CYR61 cDNA
Full length human CYR61 cDNA was isolated from a random and oligo(dT)-primed human placental cDNA library cloned into lgt11 (Clontech). As a probe for library screening we used a cDNA fragment generated by PCR of cDNAs reverse transcribed from total RNA isolated from logarithmically growing W138 cells. The sequences of the primers (H61-5 and H61-3) used in the PCR reaction were derived from the part of the coding region of the mouse cyr61 cDNA exhibiting the highest degree of conservation with other members of the gene family (Bork, 1993; O'Brien and Lau, 1992) . H61-5: 5'-GGGAATTCTG(TC)GG(GATC)TG(TC)TG(TC)AA(GA)-GT(GC)TG-3' (EcoRI site and nt 327 ± 346) and H61-3: 5'-CCGGATCC (GA) CA (GA) TT (GA)TA(GA)TT(GA)CA-3' (BamHI site and nt 1236 ± 1250). Following initial screening and subsequent plaque puri®cations, the isolated CYR61 cDNA was cloned into the pBlueScript SK + vector (Stratagene) and sequenced with the Sequenase II kit (US Biochemicals).
Northern blot analysis
Multiple tissue Northern blot (Clontech) of adult human mRNA was hybridized in the ExpressHyb Solution (Clontech) according to the manufacturer's instructions. Total cellular RNA was isolated from human skin ®broblasts (HSFs) by using a guanidinium isothiocyanate protocol (Chomczynski and Sacchi, 1987) . RNA samples were analysed by electrophoretic separation in formaldehyde-agarose gels followed by transfer to nylon ®lters. Blots were hybridized with 32 P-labeled cDNA probes of hCYR61, CTGF (Bradham et al., 1991) , novH (Martinerie et al., 1994) or b-actin.
Insect cell culture and puri®cation of recombinant hCYR61
The SmaI ± HindIII fragment (nt 100 ± 1649) of the human CYR61 cDNA, which encompasses the entire open reading frame, was cloned into pBlueBac3 baculovirus expression vector (Invitrogen). Recombinant baculovirus clones were obtained, plaque-puri®ed and ampli®ed through three passages of Sf9 insect cell infection as described (Summers and Smith, 1987) . Infection of Sf9 cells and hCYR61 puri®cation were performed essentially as described for the mouse Cyr61 (Kireeva et al., 1996 (Kireeva et al., , 1997 with some modi®cations. Sf9 cells were maintained in serum-free Sf900-II medium (Gibco BRL). Sf9 cells were seeded at 2 ± 3610 6 cells/P150 in monolayer cultures and were infected with 5 PFU of recombinant virus per cell. The conditioned medium was collected 48 and 96 h postinfection, cleared by centrifugation (5000 g, 5 min) and adjusted to 50 mM MES (morpholineethanesulfonic acid), pH 6.0, 1 mM PMSF (phenylmethylsulfonyl¯uoride), 1 mM EDTA. The medium was mixed with Sepharose S beads equilibrated with the loading buer (50 mM MES, pH 6.0, 1 mM PMSF, 1 mM EDTA, 150 mM NaCl) (5 ml Sepharose S/500 ml conditioned medium) and the proteins were allowed to bind to the Sepharose S in a batch (48C, o/n) with gentle stirring. Sepharose S beads were collected (sedimentation without stirring, 20 min) and applied to the column. The column was washed with six volumes of the 0.3 M NaCl in the loading buer adjusted to 0.3 M NaCl and the bound proteins were eluted from the column with a step gradient of NaCl (0.4 ± 0.8 M) in the loading buer.
Thymidine incorporation assay
HUVECs were plated on 48-well plates (Falcon) in complete F12 medium at indicated densities and allowed to attach overnight. Next morning the medium was changed to Human Endothelial SFM Basal Growth Medium (Gibco BRL). According to the manufacturer this media contains heparin, but does not contain serum adhesion molecules or growth factors. After 24 h of incubation in growth factor-free Endothelial SFM Medium, hCYR61 protein or protein storage buer, [ 3 H]thymidine (1 mCi/ml ®nal concentration, ICN), bFGF (Gibco BRL) and anti-Cyr61 polyclonal antibody were added simultaneously in fresh Endothelial SFM Medium. Triplicate wells were used for each condition tested. After indicated times of incubation the cells were washed with PBS and ®xed with 10% trichloroacetic acid. DNA was dissolved in 0.1 N sodium hydroxide, 0.2% SDS and the thymidine incorporation was counted.
Preparation of dishes coated with ECM
Plates coated with cell-free subendothelial extracellular matrix was prepared as described (Vlodavsky et al., 1987) . Brie¯y, HUVECs were grown in 6-well plates (Falcon) as described above, culture media was changed every 3 days. Four to 5 days after the cells reached con¯uence, the subendothelial ECM was exposed by dissolving the cell layer (3 min, room temperature) with a solution containing 0.5% Triton X-100 and 20 mM ammonium hydroxide in PBS, followed by four washes in PBS. The ECM remained free of cellular debris as judged by light microscopy.
Iodination of bFGF
bFGF was iodinated essentially as described (Vlodavsky et al., 1987) . Brie¯y, bFGF in 0.2 M sodium-phosphate buer, pH 7.2 was labeled with 125 I (Na 125 I, 333 mCi/ml, NEN) in the presence of Iodo-Beads (Pierce) (5 min, room temperature). The reaction mixture was then applied onto a small Heparin Sepharose CL-6B (Pharmacia) column equilibrated with 0.6 M sodium chloride in 20 mM sodium phosphate buer, pH 7.2. The column was washed with the same buer and the 125 I-bFGF eluted with phosphate buer containing 2 M sodium chloride, 0.1% Triton X-100 and 0.2% BSA. The speci®c activity of the iodinated preparations was 10 5 c.p.m./ng bFGF.
Release of ECM-bound bFGF
Binding to ECM-coated plates and subsequent release of iodinated bFGF were performed as described (Vlodavsky et al., 1987) . ECM-coated plates prepared as described above were preheated (1 h, 808C) to inactivate possible proteolytic activity residing in the ECM. The ECM was incubated with iodinated bFGF (2.5610 4 c.p.m./well) overnight at room temperature and the unbound factor removed by four washes of PBS containing 0.02% BSA. ECM was then incubated with hCYR61 or storage buer diluted in PBS-BSA solution and aliquots of the incubation medium were counted in a b-counter to determine the amount of released iodinated material.
The remaining ECM was washed twice with PBS, solubilized with 1 M sodium hydroxide, and the radioactivity counted in a b-counter. The percentage of released 125 I-bFGF was calculated from the total ECM-associated radioactivity.
